270 related articles for article (PubMed ID: 19727076)
1. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Lauchle JO; Kim D; Le DT; Akagi K; Crone M; Krisman K; Warner K; Bonifas JM; Li Q; Coakley KM; Diaz-Flores E; Gorman M; Przybranowski S; Tran M; Kogan SC; Roose JP; Copeland NG; Jenkins NA; Parada L; Wolff L; Sebolt-Leopold J; Shannon K
Nature; 2009 Sep; 461(7262):411-4. PubMed ID: 19727076
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A; Ellegast JM; Alexe G; Frank ES; Ross L; Chu SH; Pikman Y; Robichaud A; Goodale A; Häupl B; Mohr S; Rao AV; Walker AR; Blachly JS; Piccioni F; Armstrong SA; Byrd JC; Oellerich T; Stegmaier K
Cancer Discov; 2020 Feb; 10(2):214-231. PubMed ID: 31771968
[TBL] [Abstract][Full Text] [Related]
3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
5. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
6. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Morgan MA; Dolp O; Reuter CW
Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
[TBL] [Abstract][Full Text] [Related]
10. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Mattingly RR; Kraniak JM; Dilworth JT; Mathieu P; Bealmear B; Nowak JE; Benjamins JA; Tainsky MA; Reiners JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):456-65. PubMed ID: 16239399
[TBL] [Abstract][Full Text] [Related]
11. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
Mahgoub N; Taylor BR; Gratiot M; Kohl NE; Gibbs JB; Jacks T; Shannon KM
Blood; 1999 Oct; 94(7):2469-76. PubMed ID: 10498620
[TBL] [Abstract][Full Text] [Related]
13. A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells.
Roose JP; Mollenauer M; Gupta VA; Stone J; Weiss A
Mol Cell Biol; 2005 Jun; 25(11):4426-41. PubMed ID: 15899849
[TBL] [Abstract][Full Text] [Related]
14. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
[TBL] [Abstract][Full Text] [Related]
16. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
18. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence.
Wang W; Chen JX; Liao R; Deng Q; Zhou JJ; Huang S; Sun P
Mol Cell Biol; 2002 May; 22(10):3389-403. PubMed ID: 11971971
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
